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Abstract
Background: Anthracyclines are chemotherapeutic agents frequently used in breast cancer (BC) treatment. Although it
improves disease-free and overall survival, the use of anthracyclines is associated with a cumulative risk of cardiac toxicity.
Preventive strategies to optimize cardiac health are needed and exercise is proposed as a potential non-pharmacological
approach for counteracting anthracycline-related cardiotoxicity (ARC). Most of the data on the effects of exercise to
reduce ACT are from animal studies, with only a few studies in a limited number of patients indicating beneficial effects.
To better understand the effectiveness of exercise in the mitigation of ARC, clinical, real-world trials claim require a larger
sample size and more accurate and valuable clinical biomarkers. In this study, we intend to include a large sample and
investigate cardiac function through serial measures of biomarkers and imaging techniques.
Methods: This protocol describes a two-arm, prospective, randomized controlled trial that will explore the
cardioprotective effect of a structured exercise program in women with BC undergoing anthracycline-containing
chemotherapy (ACT). Ninety adult women with early BC and recommended to receive ACT will be randomly assigned
(1:1) to an intervention group or a control group. Patients allocated to the intervention group will perform a supervised
exercise program three times per week, consisting of a combination of aerobic and resistance training with progressive
intensity and volume, during the time period they receive ACT. The control group will receive standard BC care. Primary
outcomes related to cardiac (dys)function will be circulating N-terminal pro-brain natriuretic peptide (NT-proBNP) levels,
resting left ventricular (LV) longitudinal strain, and resting LV ejection fraction. Secondary outcomes will include the
assessment of resting blood pressure, resting heart rate (HR), resting HR variability (HRV), recovery HR, physical
function outcomes, self-reported physical activity level, health-related quality of life, and fatigue. Data will be
obtained at baseline (t0), after the end of anthracycline-treatment (t2), and 3 months after t2 (t3). Additionally,
NT-proBNP will be measured 1–24 h prior to each anthracycline-treatment cycle (t1).
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Discussion: The implementation of the present study design, using novel clinical biomarkers, will determine
the effect of structured exercise interventions at mitigating ARC, with the overall aim of finding means to
further improve BC care.
Trial registration: ISRCTN, ISRCTN32617901. Registered on 24 October 2018. Last updated on 11 January 2019.
Keywords: Breast cancer, Cardiotoxicity, Cardiac healthcare, Supervised exercise, Supportive cancer care
Background
Over the last three decades the epidemiology of breast
cancer (BC) has been marked by the clear increase in
survival rates [1]. The accessibility of screening and the
discovery of new therapeutic options are among some
relevant factors related to the improved management of
cancer. However, despite their undeniable clinical im-
portance, anti-cancer treatments are also associated with
frequent induction of side effects. Among those, cardio-
toxicity emerges as a major challenge, limiting treatment
options [2] and contributing to morbidity and mortality
in this patient population [3–5].
In the BC setting, cardiotoxicity is typically associated
with exposure to traditional cytotoxic therapies and par-
ticularly with the use of anthracyclines [6]. Anthracyclines
are important and effective chemotherapeutic agents, fre-
quently administered in curative and palliative regimens for
BC, although their clinical use is limited by cardiac dysfunc-
tion, usually seen as cardiotoxicity [7]. The American So-
ciety of Echocardiography and European Association of
Cardiovascular Imaging define cardiotoxicity as a decrease
in left ventricular ejection fraction (LVEF) of > 10% to a
value of < 53% [8]. However, it has been proposed that
anthracycline-related cardiotoxicity (ARC) is a continuous
[9] and dose-dependent phenomenon [10] that starts with
acute myocardial damage [11], which can be detected by
elevation of circulating cardiac biomarkers [12] and by
impairment of left ventricular (LV) longitudinal strain [13],
in turn preceding the commonly reported progressive
decline in LVEF [9]. ARC may ultimately lead to overt heart
failure, particularly when underestimated, not prevented or
insufficiently prevented, or untreated, [9].
Unfortunately, and in addition to the manifestations
associated with anthracycline treatment, BC survivors
often exhibit a phenotype characterized by the presence
of risk factors for cardiovascular disease (CVD), includ-
ing advanced age, obesity, prior CVD, poor cardiorespi-
ratory fitness, and inappropriate lifestyle (smoking,
alcoholism, and sedentary lifestyle) [14, 15]. It is there-
fore not surprising that when compared to healthy indi-
viduals of a similar age, these patients have higher
prevalence of CVD and greater mortality [4]. Consider-
ing the high risk of cardiac dysfunction, the study of
preventive strategies is an emerging and unmet need, as
these strategies may mitigate cardiac damage associated
with the use of cardiotoxic agents and could lead to im-
provements in overall cardiovascular health.
In adults with CVD without cancer, exercise training is
recognized as an important approach in cardiac rehabili-
tation [16]. Particularly, two meta-analyses have shown
favorable effects of exercise on attenuation of N-
terminal pro-brain natriuretic peptide (NT-proBNP) [17]
and mitigation of LV remodeling [18] in patients with
heart failure. Also, in the oncological setting, it has be-
come clear that exercise is a safe and effective supportive
therapy in the management of several treatment-related
side effects and in improving overall physical fitness [19,
20]. Furthermore, in a recent position paper the Euro-
pean Society of Cardiology task force for cancer treat-
ments and cardiovascular toxicity suggests the possible
utility of aerobic exercise as a promising strategy to at-
tenuate ARC [21]. However, this position remains to be
complementarily analyzed as the evidence so far is
mainly from studies in animal models [22, 23], with only
a few studies in a limited number of patients to evaluate
the cardioprotective role of exercise in cardiac function
among women with breast cancer receiving cardiotoxic
treatments [24–26]. Further clinical studies involving a
large sample size and accurate clinical biomarkers are
thus warranted to better understand the effectiveness of
exercise in the mitigation of ARC.
Hypothesis
The primary aim of this study is to ascertain whether a
structured exercise program mitigates ARC, measured
by change in the levels of circulating biomarkers (NT-
proBNP) and cardiac (dys)function endpoints (LV global
longitudinal strain and LVEF). The secondary aim is to
evaluate the effectiveness of the intervention in the regu-
lation of some cardiac health parameters: resting blood
pressure, resting heart rate (HR), resting HR variability
(HRV) and recovery HR. As exploratory objectives, we
will assess physical function (cardiorespiratory capacity,
upper limb strength, and lower limb functionality), self-
reported physical activity level, health-related quality of
life (HR-QOL), and fatigue. We hypothesize that exer-
cise may limit the degradation of cardiac function
and structure and benefit cardiac outcomes. We also
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believe that patients in the intervention group will
improve overall physical fitness, HR-QOL, decrease




This is a study protocol for a two-arm, prospective,
randomized controlled trial that will explore the cardio-
protective effect of a structured exercise program, com-
pared to standard care, in adult women undergoing
anthracycline-containing chemotherapy (AC-CT) for
early BC. The study design and protocol adhere to the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (Additional file 1).
The study design is outlined in Fig. 1.
Ethical approval
This study will be conducted in compliance with the
Declaration of Helsinki Ethical Principles (1975) and it
received approval by the Ethics Committee of the Centro
Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E;
Vila Nova de Gaia, Portugal) (reference number: 145/
2018–1). The study is registered in the International
Standard Randomised Controlled Trial Number
(ISRCTN32617901). Any protocol amendments will be
submitted to the CHVNG/E for ethical approval and up-
dated on the ISRCTN.
Participant recruitment
We intend to recruit 90 adult women with early in-
vasive BC, scheduled to receive AC-CT and followed
up in the Medical Oncology Department of the
CHVNG/E. Participants will be recruited based on
the eligibility criteria presented in Table 1. Recruit-
ment will take place in two distinct phases. In the
first instance, potential participants will be identified
in the multidisciplinary consultation involving med-
ical oncologists, surgeons, and radio-oncologists.
After this preliminary phase, the eligibility of each
patient will be confirmed by the oncologist during a
medical consultation. The oncologist will present the
study to the patients who are considered eligible,
explaining the study, offering participation and
requesting written informed consent. Written in-
formed consent will be obtained from all patients
and they will be informed that they are under no
obligation to participate and they may withdraw
their consent at any time. Withdrawal from the
study or non-participation will have no consequences
for medical follow up and care. Where possible, the
reasons for withdrawal from the study will be re-
corded. All the participants will be followed from
the acceptance period (t0) and 3 months after the
end of the AC-CT (t3). If recruitment is not achiev-
ing the target sample size, we will extend recruit-
ment to additional hospitals.
Randomization
After confirmation of eligibility and baseline assess-
ments (t0), patients will be randomized using Inter-
net software (www.sealedenvelope.com), in a 1:1
ratio to the supervised exercise group (intervention
group) or the usual care group (control group),
using a permutated block design with random block
sizes (4, 6, 8) with stratification by two dichotomous
variables, which are known risk factors for ARC:
 Age (< 50 years or older)
 Receiving anti human epidermal growth factor
receptor 2 (anti-HER2) therapy (yes/no)
This process will be performed by an external
individual who is blinded to the study and who will
place the sequence in a numbered, opaque, sealed
envelope. The allocation of participants will then be
reported to an oncologist (AJ) who will subsequently
inform the patients about the assignment group.
Study arms
Intervention group
Patients allocated to the intervention group will perform
a supervised exercise program specifically developed for
patients with BC, based on the guidelines of the Ameri-
can College of Sports Medicine [27] and in a close co-
operation between physical sports researchers (PA, DE,
AA) and medical staff (oncologists, surgeons, radiolo-
gists, physiatrist, and physiotherapist) of the CHVNG/E.
The exercise program comprises three sessions per week
guided in small groups (< 5 patients) in an appropriately
equipped room at the CHVNG/E, supervised by the
main author (PA) and a physiotherapist. Each session
will involve an initial warm up (5 min), followed by re-
sistance and aerobic training (60 min), and ending with a
cooldown phase (5 min). The program will be started 1–
2 days after the first AC-CT session and will be con-
ducted over the respective treatment of each patient. It
should be noted that the proposed exercise intervention
will never be intended to replace or interfere with the
current standard BC care.
Aerobic training It will include the combination of
treadmill, stationary bike, and stepping. This phase
will be monitored through HR (each participant will
wear a HR monitor during exercise training sessions)
and rate of perceived exertion (RPE) measured by a
0–10 point modified Borg scale (minimal effort = 0;
maximum effort = 10) [29]. During the first 2 weeks,
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Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Female gender Contraindications to maximal exercise testing
Decompensated diabetes mellitus
Aged 18 years or older Severe anemia (hemoglobin < 8 g/dL) uncorrectable with transfusion
and/or iron and/or vitamin deficiency replacement
Pregnancy
Histological diagnosis of stage IA–IIIC breast carcinoma Known significant heart disease (myocardial infarction,
congestive heart failure, cardiomyopathy)
Scheduled to receive AC-CT Usual medication containing beta-blockers
Follow up at the Medical Oncology clinic at the CHVNG/E
Consent of the assistant oncologist for the practice of exercise
Able to provide informed consent
Acceptance of randomization to intervention group or control group
AC-CT anthracycline-containing chemotherapy, CHVNG/E Centro Hospitalar de Vila Nova de Gaia/Espinho
Fig. 1 Study flow. ACH, anthracycline-containing chemotherapy; SBCC, standard breast cancer care; SEP, structured exercise program
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the participants will perform 20 min (divided equally
among the three exercise modes) of light-intensity,
aerobic training (at < 50% of measured HR reserve
(based on maximum HR reached in the cardiorespira-
tory test), with a reported rating of 2–4 (“easy” to
“somewhat easy”) on the modified Borg scale). After
this period, 3 min will be added every 2 weeks until a
volume of 30 min of aerobic training is reached. At
this stage, participants will be encouraged to perform
moderate-intensity to high-intensity training (at 65–80%
of measured HR reserve, with a reported rating of 5–8
(“somewhat hard” to “hard”) on the modified Borg scale)
until the end of the intervention.
Participants will be reminded weekly (by email and
phone) of their exercise training schedule and the
importance of adherence, to achieve the established
objectives.
Resistance training Resistance training will include
upper body (shoulder press, chest press, lateral pull-
down, biceps curls, and triceps extension) and lower
body (squat, calf raise, leg press, leg extension, and leg
curl) weight-training exercises. All the exercises will be
performed at the maximum possible joint range of
motion, using resistance machines and free weights. RPE
will be measured using a 0–10-point OMNI-Resistance
Exercise Scale (OMNI-RES, minimal effort = 0; max-
imum effort = 10) [28]. During the first week, partici-
pants will perform 2 sets and 10 repetitions of each
exercise without additional resistance or with the lowest
available (reported rating of 2–4 (“easy” to “somewhat
easy”) on the OMNI-RES). After this phase, if no adverse
events or symptoms were reported for a specific exer-
cise, resistance will be added so that each participant
could be able to perform 3 sets with 12 maximal repeti-
tions (12-RM) of each exercise. When the participants
can complete 3 sets and more than 12-RM at the set
weight in three consecutive sessions, then the resistance
will be increased by between 5% and 10%.
Usual care group
Patients allocated to the usual care group (CG) will re-
ceive standard BC care. The usual CG will not receive
any specific advice about physical activity and will not
be asked to be inactive. In compensation for participa-
tion in this study, patients in this group will be offered
the possibility to follow the same exercise program as in
the intervention group, after the final assessments are
completed.
Study assessments
The schedule of study outcome assessments is outlined in
Fig. 2. Study assessments will be scheduled upfront and
participants will be regularly reminded (by email and
phone) to ensure complete follow up. Primary, secondary,
and exploratory outcomes will be measured in all partici-
pants at three different time points:
 t0 (baseline assessments): between 0 and 14 days
prior to the first chemotherapy session
 t2 (post-treatment assessments): between 1 and 5
days after the end of AC-CT
 t3 (follow-up assessments): after 3 months of t2
In addition, for analysis of circulating NT-proBNP,
blood samples will be collected between 1 and 24 h be-
fore each AC-CT cycle (t1: during treatment assess-
ments). Patients will be instructed and reminded to
avoid drinking beverages containing alcoholic or caf-
feine, and to abstain from smoking for 12 h prior to, and




The primary outcomes are:
 Circulating NT-proBNP levels
 Resting LV global longitudinal strain
 Resting LV ejection fraction
Secondary outcomes
The secondary outcomes are:
 Cardiac health outcomes:






– Upper limb strength
– Lower limb functionality
 Self-reported physical activity level
 Health-related quality of life
 Fatigue
Assessment of the primary outcomes
Resting LV ejection fraction and resting LV longitudinal
strain
Resting LV ejection fraction will be calculated using the
biplane method of disks (modified Simpson’s rule) from
the apical four-chamber and two-chamber view [30]. For
resting LV global longitudinal strain assessment, two-
dimensional grayscale images will be acquired in the apical
four-chamber, two-chamber, and three-chamber views,
with a frame rate of 60–100 frames per s (fps). Three
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cardiac cycles will be digitally stored and Velocity Vector
Imaging (VVI) software (Siemens Medical Solutions
United States of America Inc) will be used in the analysis.
Echocardiographic acquisitions will be performed by a
single experienced cardiologist blinded to the patient as-
signment group.
Circulating NT-proBNP levels
Non-fasting venous blood samples will be drawn by a
nurse oncologist. The assessment of NT-proBNP levels
will be conducted in the local clinical analysis laboratories
at the CHVNG/E, which are certified by the UK National
External Quality Assessment Service. These professional
staff will be blinded to the patient assignment group.
Assessment of the secondary outcomes
Resting blood pressure and resting HR
Resting blood pressure (systolic and diastolic blood pres-
sure) and resting HR will be measured using a standard
automated device (Philips SureSignsVM6 (Philips Me-
dical System, Andover, USA)). Two measurements will
be carried out. The first measurement will be preceded
by a 5-min resting period and a second reading will be
taken after 3 min. If necessary, additional records shall
be obtained until two consecutive stable measurements
Fig. 2 The schedule of enrolment, interventions, and assessments. -t0, enrolment process; t0, baseline; t1, during anthracycline-containing
chemotherapy; t2. post anthracycline-containing chemotherapy (which coincides with the end of the intervention); t3, 3 months after t2;
NT-proBNP, N-Terminal pro-brain natriuretic peptide; LV, left ventricular
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(differences < 5 mmHg for blood pressure and < 7 bpm
for HR) are obtained. The average of the two stable
measurements will be used in the analysis. This proce-
dure will be carried out by a study investigator (ALA)
not blinded to the patient assignment group.
Resting HRV
HRV is a non-invasive method used to analyze cardiac
autonomic function through the measurement of succes-
sive heartbeat variations (R-R). Resting HRV will be ana-
lyzed using a HR monitor Polar V800 (Polar Electro Oy,
Kempele, Finland) with a Polar H7 chest strap. During
the R-R recording, patients will be seated in a comfor-
table position. They shall be required to breathe spon-
taneously, to avoid any movements, and to maintain
neutral thoughts during the data acquisition. The first 5
min will be excluded (stabilization period) and the
remaining 5min will be used to calculate the time-domain
(standard deviation of successive normal R-R (SDNN),
and root mean square of successive normal R-R (RMSSD))
and frequency-domain indices (low-frequency spectral
component (LF), and high-frequency spectral component
(HF)). In all cases, the R-R recordings will be exported to
the Kubios v2 HRV software (Biosignal Analysis and
Medical Imaging Group at the Department of Applied
Physics, University of Kuopio, Kuopio, Finland). Occa-
sional artifact noise shall be automatically replaced with the
interpolated adjacent RR interval values (filter power < low).
This procedure will be carried out by the first author (PA)
who will not be blinded to the patient assignment group.
Recovery HR
Recovery HR will be determined as the absolute difference
between the HR at peak effort during the cardiorespira-
tory exercise test (CRET) and the HR at 60 s, and 120 s
post-exercise. HR values will be derived from a continuous
record obtained via CRET (Mortara X-Scribe, Mortara,
USA). This procedure will be carried out by study investi-
gators (EV, MT), blinded to the patient assignment group.
Cardiorespiratory fitness
Cardiorespiratory fitness will be evaluated by means of a
symptom-limited CRET on a treadmill (Mortara X-Scribe,
Mortara, USA), using a modified version of the Bruce
protocol [31]. Expired gases will be continuously collected
throughout exercise and analyzed for ventilatory volume
(VE) and for oxygen (O2) and carbon dioxide (CO2) con-
tent, using dedicated analyzers. Standard spirometry
(forced expiratory volume in 1 s (FEV1)) and forced vital
capacity (FVC) will also be undertaken before the test.
Equipment calibration and measurements will be in
accordance with the recommendations of the American
Thoracic Society and American College of Chest Physi-
cians [32]. The following parameters will be calculated
and considered for analysis: peak oxygen consumption
(peak V̇o2, measured in milliliters per kilogram per mi-
nute), peak respiratory exchange ratio (RER), defined by
the ratio of CO2 production to O2 consumption at peak
effort, oxygen consumption at the anaerobic threshold
(AT), defined as the point at which CO2 production
increases disproportionately in relation to O2 consump-
tion, obtained from a graph plotting O2 consumption
against CO2 production, and total exercise duration (mea-
sured in seconds). The maximum HR achieved will also
be recorded. The CRET will be conducted on a separate
day to the remaining outcomes assessments out by study
investigators (EV, MT) blinded to the patient assignment
group. Patients will be in a fasted state and will not be
asked to discontinue current medication before the test.
Upper limb strength
Upper limb strength will be evaluated by maximal vol-
untary grip strength (measured in kilograms), using a
digital handgrip dynamometer (Saehan Corporation,
Masan, South Korea - model SH5003). Each subject will
perform six trials, three in each arm, with an alterna-
ting bilateral sequence. The results will based on the
average of the three trials, respectively. This procedure
will be carried out by the first author (PA), not blinded
to the patient assignment group.
Lower limb functionality
Lower limb functionality will be evaluated by the sit-to-
stand test using a straight-backed chair (40 cm high).
Each subject will be required to keep plantar support
while flat on the floor with arms crossed at the chest,
and sit and stand as many times as possible for 30 s.
The score for the test will be determined by the number
of repetitions achieved during this procedure. The pro-
cedure will be carried out by the first author (PA), not
blinded to the patient assignment group.
Self-reported physical activity level
The International Physical Activity Questionnaire-Short
(IPAQ-SF) will be used to calculate the metabolic
equivalent (MET) minutes per week spent in walking
and in moderate and vigorous activities. Sedentary
behavior will be determined based on time spent sitting
per day (minutes). Based on their scores, participants
will be categorized as having a low, moderate, or high
physical-activity level. The Portuguese language version
of the IPAQ-SF will be used [33]. Scoring will be ana-
lyzed by the first author (PA), not blinded to the patient
assignment group.
Health-related quality of life and fatigue
The European Organization for Research and Treatment
in Cancer (EORTC) Quality of Life C-30 (QOL-C30) is a
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self-administered, validated questionnaire to assess HR-
QOL in patients with cancer [34]. It is composed of nine
multi-item scales: five functional scales (physical, role,
cognitive, emotional, and social), three symptom scales
(fatigue, pain, and nausea and vomiting), and a global
health and quality-of-life scale. Additionally, there are
five single items of symptoms commonly reported by
patients with cancer (dyspnea, sleep disturbance, appe-
tite loss, constipation, and diarrhea), and an item that
evaluates the perceived financial impact of the disease.
In this study, the third version of this questionnaire will
be used, in the Portuguese language [35]. Analyses will
include the five functional scales, fatigue scale, and the
global health and quality-of-life scale. The scoring of the
several scales will be carried out by the first author (PA),
not blinded to the patient assignment group.
Demographic, anthropometric, and clinical data
Demographic, anthropometric, and clinical data will be
recorded during the enrolment process (−t0). Demo-
graphic data include age, sex, and education. Anthropo-
metric data include weight, height, and body mass index.
Clinical data include disease, treatment information, past
medical history, and current medication. These data will
be extracted from the patients’ electronic medical files
by two study coordinators (ALA, AJ) not blinded to the
patient assignment group.
Safety
The safety of the intervention will be assessed by weekly
tracking and monitoring the number of adverse events
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 4.0 (https://
ctep.cancer.gov/protocoldevelopment/electronic_applica-
tions/ctc.htm). A meeting between the study investigators
will be held weekly to review and discuss the reported
adverse events. All serious adverse events will be imme-
diately reported to the CHVNG/E ethics commission and
to all study members, and will be reported in the study
results. Adverse events will be evaluated by the study
investigators who will make the decision to stop the study
early if there is a clinically relevant increased risk.
Data management
Study data will be managed by two study investigators
(PA, AJ) using a predesigned data collection form (Micro-
soft Office Excel version 2016 (Microsoft Corporation,
Redmond, WA, USA) and Statistical Package for the So-
cial Sciences files version 23.0 (IBM Corporation,
Armonk, NY, USA)) with double data-entry. Data checks
will be regularly performed to ensure data quality. Patients
will be identified by codes to ensure their anonymity, and
only the authors involved in the trial will have access to
their full identification details. The total number of
patients who meet the study eligibility criteria will be re-
corded, as will the number of patients who agree or not
agree to participate in the study, the number of patients
assigned to each study arm, the number of patients who
participate in all sessions, the attendance of each patient
in the intervention sessions, the number of patients who
provide follow-up data, the number of patients included
in the final analysis, and the number of withdrawals.
Sample size calculation
The sample size was determined by a power calculation
based on resting LVEF outcome, using a non-commercial
statistical power analysis program (G*Power Version
3.1.9.2). Based on an effect size of 0.6 for resting LVEF
presented in a previous study [26], to ensure statistical
power of 80% and a significance level of 0.05, using the t
test for two independent groups, the recruitment of 72
participants is required. Predicting a 20% dropout rate
[19], we estimate that a total of 90 patients will be needed
(45 in each arm). There are no planned early stopping
rules. Adverse events will be evaluated by the study inves-
tigators, who will make the decision to stop the study early
if there is a clinically relevant increased risk.
Statistical analyses
Statistical data analysis will be performed using the Statis-
tical Package for the Social Sciences. The statistical signifi-
cance will be set at a p value <0.05. Intention-to-treat and
per-protocol approaches will be used both for all analyses.
Data analysis will start with standard descriptive methods
to describe the data (means and standard deviations will
be calculated for continuous variables and absolute and
relative frequencies for categorical variables).
Continuous variables will be compared between the
two study groups using one-way analysis of covariance
(ANCOVA), adjusted for the effect of the baseline values
(covariate). A linear two-way mixed ANCOVA model
with repeated measures (t1, t2 and t3) will be performed
to test the difference over time between the two study
groups and interaction (Group × Time), on primary and
secondary outcomes, with the same covariate as the
one-way ANCOVA. Bonferroni’s post-hoc procedure will
be performed to locate the pairwise differences. Norma-
lity will be verified by the Kolmogorov-Smirnov test and
the homogeneity of the variance will be validated by
Levene’s test. Effect size will be calculated to estimate
variance between moments through partial eta-squared.
The cutoff values were defined as 0.02 for small effect
size, 0.13 for moderate, and 0.26 for large effect sizes
[36]. The chi-squared test will be used to check for a
relationship between categorical variables. The effect size
will be calculated using Cramer’s V test and interpreted
based on the following cutoff values: 0.10 for a small
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effect, 0.30 for a medium effect, and 0.50 for a large
effect. [36] No interim analyses will be conducted.
Blinding
This study will involve the prescription of exercise ses-
sions. To carry out a rigorous exercise prescription and to
ensure adequate follow up of each patient, participants,
the physical trainer (PA), the medical oncologist (AJ), and
the nurse oncologist (ALA) will not be blinded to group
assignment. Due to the lack of resources, only the evalua-
tors acquiring the echocardiographic outcomes (resting
LVEF and LV global longitudinal strain), circulating NT-
proBNP levels, cardiorespiratory fitness, and recovery HR
data, will be blinded to the group assignment.
Limitations
There are some limitations to this study, which should be
noted. First, we will only include patients followed at
CHVNG/E. Second, due to the impossibility of blinding
patients and some of the researchers to study group
assignment, the open design of this study may influence
the assessment retention rate of participants allocated to
the control group. Third, we will stratify our sample based
on age (under/over 50 years) and use of trastuzumab (yes/
no). However, there are other risk factors associated with
ARC, including total cumulative anthracycline dose, pre-
existing cardiac disease, and treatment with mediastinal
radiation, that should also be considered [19]. Although
these hinderances should be acknowledged, we believe the
findings from the present study will provide important
data, which will be of relevance to the contemporary lit-
erature on this subject.
Dissemination
The findings of this study will be reported in a doctoral
thesis by the main author, will be submitted to a peer-
reviewed journal for publication, and will be presented at
relevant conferences and disseminated to the public in
partnership with CHVNG/E, Universidade da Beira Inte-
rior (Covilhã, Portugal), and community stakeholders.
Discussion
CVD is one of the leading causes of death among women
with BC [3–5] and a foremost concern in the clinical prac-
tice of oncology [2]. According to Gernaat et al. [4], BC
survivors have an absolute risk of dying from CVD that
ranges from 1.6% to 10.4%. The recurrent use of car-
diotoxic therapies and the presence of risk factors for the
development and worsening of cardiovascular health prob-
lems are the main factors related to this phenomenon. The
implementation of preventive strategies aiming to optimize
cardiovascular care in BC survivors is therefore an emer-
ging need. To date these include early identification of
potential risk factors, the management of anthracycline
cumulative dose (and possible use of ancillary therapies), or
the use of drugs for heart failure (beta-blockers, angiotensin
converting enzyme inhibitors, and angiotensin receptor
antagonists) [21]. However, these approaches were mainly
established to reduce the toxicity of therapeutic agents and
ensure their efficacy, but not to provide a general preven-
tive cardiovascular approach. It is thus pivotal to investigate
the effects of non-pharmacological prevention strategies in
order to counteract ARC and related complications in
patients with BC.
Currently, exercise is recognized as a safe and effective,
supportive intervention to improve physical function and
HR-QOL in BC survivors during [19] or after treatment
[20]. Furthermore, exercise has also been proposed as a
potential tool to mitigate ARC in humans [21, 37],
although this remains uncertain as it is mainly supported
by data from animal studies and/or using less accurate
biomarkers [22, 23]. In fact, there are limited data on
whether the benefits of exercise also include protection
from anthracycline-related cardiac damage in women with
BC. To the best of our knowledge, Kirkham et al. [24]
were the first to test this hypothesis by analyzing the
efficacy of a single aerobic bout performed 24 h prior to
each treatment. The authors observed positive effects on
systemic outcomes (cardiac output, resting HR, body
weight, and psychological symptoms), but did not observe
relevant changes in echocardiographic outcomes (LV
mass, LV ejection fraction, strain imaging, and the E/A
ratio) or circulating cardiac biomarkers (troponin t and
NT-proBNP). In a recent non-randomized trial, Howden
et al. [26] verified that performing a 2-weekly supervised
exercise program plus a weekly unsupervised aerobic ses-
sion attenuated the reduction in peak Vo2 and the in-
crease of troponin levels in women with BC undergoing
AC-CT, when compared to a usual care group. However,
these authors did not observe any relevant changes in the
measured echocardiographic outcomes. So far, the overall
clinical significance of exercise in preventing cardiac
dysfunction associated with anthracycline treatment re-
mains to be clarified in controlled clinical settings.
The present study will explore the cardioprotective
role of exercise and potential mitigation of ARC, and es-
tablish the possible effect of exercise on different health
outcomes in women with BC. A total of 90 adult women
with early BC and prescribed AC-CT at the CHVNG/E
will be enrolled. Recruitment will take place between 1
November 2018 and 31 November 2020 (expected date
of recruitment completion). Follow up is expected to be
completed by 30 June 2021.
We anticipate that the results of this study will add
new knowledge to what the literature currently offers,
clarifying the effects of a supervised exercise program on
different established markers and more accurate bio-
markers of cardiotoxicity in women with BC undergoing
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AC-CT. Furthermore, we expect that the findings from
this study may help in future policies related to cancer
care management and contribute to the ascertainment
of the role of exercise programs during anti-neoplastic
treatment in hospital.
Trial status
Recruitment started on 1 November 2018 and is expected
to be completed by 31 November 2020. Last edited, 11
January 2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 127 kb)
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